ライフサイエンスコーパス: epoetin alfa

1 a heavily glycosylated protein therapeutic (Epoetin Alfa).

2 fusion and recombinant human erythropoietin (epoetin alfa).

3 eable with recombinant human erythropoietin (epoetin alfa).

4 948 to 3831 during treatment with GM-CSF +/- epoetin alfa.

5 o define the optimal doses and schedules for epoetin alfa.

6 Hb levels increased from baseline with epoetin alfa.

7 nt is somewhat greater with continued weekly epoetin alfa.

8 which placebo patients were crossed over to epoetin alfa.

9 bel phase during which all patients received epoetin alfa.

10 23 to 28% of these patients were prescribed epoetin alfa.

11 ed hazards ratio of 1.309 (P =.052) favoring epoetin alfa.

12 AKT activation were similar for CNTO 530 and epoetin-alfa.

13 Patients received epoetin alfa 10,000 U three times weekly, which could be

14 design, the single-dose pharmacokinetics of Epoetin alfa (100 U/kg) and an equivalent peptide mass o

15 eekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120K arm) SC every 3 weeks for 18 addition

16 tarting chemotherapy, were randomized 2:1 to epoetin alfa 150 to 300 IU/kg (n = 251) or placebo (n =

17 Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be

18 io, to either GM-CSF (0.3-5.0 microg/kg.d) + epoetin alfa (150 IU/kg 3 times/wk) or GM-CSF (0.3-5.0 m

19 t between groups (observation, 35.42 months; epoetin alfa, 31.47 months; hazard ratio, 1.04; 95% CI,

20 Patients received epoetin alfa 40,000 U once weekly, which could be increa

21 enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously (SC), followed by e

22 After three weekly doses of epoetin alfa 40,000 U, a dose of 120,000 U can be admini

23 Epoetin alfa (40,000 U) or placebo was administered week

24 enter, placebo-controlled, clinical trial of epoetin alfa, 40,000 U subcutaneously, once weekly vs. m

25 sly (SC), followed by either standard weekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120

26 be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56

27 anemic critically ill patients treated with epoetin alfa, all dosing regimens were well tolerated an

28 ts who had received the Eprex formulation of epoetin alfa and 1 in a patient who had received Neoreco

29 erall tumor response was similar between the epoetin alfa and placebo groups after three chemotherapy

30 Epoetin alfa and placebo groups had similar median overa

31 Epoetin alfa and placebo patients (n = 109 and n = 115,

32 ; P=0.67) at 6 months did not differ between epoetin alfa and placebo, but declines in stroke volume

33 Percentages of patients in the epoetin alfa and the placebo groups requiring transfusio

34 s transfused during the 12-week study in the epoetin alfa and the placebo groups were 5.9 and 9.5, re

35 Mean Hb increased by 2.2 +/- 1.3 g/dL (epoetin alfa) and by 0.1 +/- 1.0 g/dL (placebo) in the D

36 ers of Eprex, Epogen (another formulation of epoetin alfa), and Neorecormon.

37 Concordantly, epoetin alfa appeared to increase hemoglobin levels and

38 Epoetin alfa appears to have a beneficial impact on pati

39 These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related

40 multiple times and pooling preservative-free epoetin alfa caused this outbreak of bloodstream infecti

41 Epoetin alfa, compared with placebo, significantly decre

42 This study assessed whether epoetin alfa could maintain RBV dose, improve quality of

43 quently can be treated via administration of epoetin-alfa, darbepoietin-alfa, or methoxy-PEG epoetin-

44 The pharmacokinetics of epoetin alfa did not predict pharmacodynamic response in

45 t that in newly diagnosed patients with SCLC epoetin alfa does not affect tumor response to chemother

46 The use of epoetin alfa does not reduce the incidence of red-cell t

47 United States with darbepoetin alfa (DA) or epoetin alfa (EA).

48 The results suggest that epoetin alfa effectively improves functional outcomes in

49 safety phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct E

50 S. liquefaciens was isolated from pooled epoetin alfa, empty vials of epoetin alfa that had been

51 ninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat

52 Epoetin alfa (EPO) robustly induced bone marrow erythrof

53 were punctured multiple times, and residual epoetin alfa from multiple vials was pooled and administ

54 the first week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV

55 ell units transfused (4.5+/-4.6 units in the epoetin alfa group and 4.3+/-4.8 units in the placebo gr

56 red in 4 of 45 (9%) patients in the GM-CSF + epoetin alfa group compared with 1 of 21 (5%) patients w

57 oncentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6+/-2.0

58 e interval {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3%

59 red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% conf

60 GM-CSF +/- epoetin alfa had no effect on mean platelet count.

61 ving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compar

62 Prescription of epoetin alfa has been associated with increased survival

63 ective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia

64 ted in patients who switched from placebo to epoetin alfa in the OLP.

65 mulating factor (GM-CSF) and erythropoietin (epoetin alfa) in anemic, neutropenic patients with myelo

66 inical trials have shown that treatment with epoetin alfa increases hemoglobin levels, reduces fatigu

67 Treatment with epoetin alfa is associated with an increase in the incid

68 Epoetin alfa is effective in improving the functional st

69 Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia

70 Epoetin alfa maintained RBV dose and improved QOL and Hb

71 erapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfu

72 s or reactions were associated with doses of epoetin alfa of more than 4000 U (multivariate odds rati

73 To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted i

74 olled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic

75 led trial (N93-004) evaluated the effects of epoetin alfa on tumor response to chemotherapy and survi

76 domly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered wit

77 a mouse model, single-dose CNTO 530 (unlike epoetin-alfa or darbepoietin-alfa) bolstered red cell pr

78 erythroblasts at frequencies multifold above epoetin-alfa or darbepoietin-alfa.

79 In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in an

80 showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test), and Cox regression

81 Fewer epoetin alfa patients than placebo patients required tra

82 s maintained in the prechemotherapy range in epoetin alfa patients, but decreased substantially in pl

83 ajority of these patients received Eprex, an epoetin alfa product marketed exclusively outside the Un

84 In conclusion, epoetin alfa provided clinically significant HRQL improv

85 One of six dosing epoetin alfa regimens for 15 days, as follows: 40,000 IU

86 inical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well a

87 Treatment with epoetin alfa resulted in significant increases in hemogl

88 Epoetin alfa safely and effectively ameliorates anemia a

89 Epoetin alfa significantly improved HgB and reduced tran

90 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-w

91 were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 1

92 were associated with higher median doses of epoetin alfa than the 188 other sessions (6500 vs. 4000

93 ted from pooled epoetin alfa, empty vials of epoetin alfa that had been pooled, antibacterial soap, a

94 ety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke

95 As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in eit

96 and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are sim

97 mmunity-based trial suggest that once-weekly epoetin alfa therapy increases hemoglobin levels, decrea

98 the 2,964 patients assessable for efficacy, epoetin alfa therapy resulted in significant increases i

99 Epoetin alfa therapy was also associated with a signific

100 Epoetin alfa therapy was associated with improved qualit

101 30, 1,047 patients completed all 4 months of epoetin alfa therapy.

102 The administration of the ESA epoetin alfa to critically ill trauma patients has been

103 Administration of epoetin alfa to older adult patients with heart failure

104 Addition of epoetin alfa to radical radiotherapy did not affect surv

105 he authors aimed to evaluate the efficacy of epoetin alfa treatment on the outcome of OHCA patients i

106 ized, double-blind clinical trial evaluating epoetin alfa versus placebo in anemic cancer patients.

107 igue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.

108 were maintained in 88% of patients receiving epoetin alfa vs. 60% of patients receiving placebo (P <

109 In addition, epoetin alfa was associated with a significant increase

110 As compared with placebo, epoetin alfa was associated with a significant increase

111 Epoetin alfa was associated with significant increases i

112 After the practice of pooling epoetin alfa was discontinued and the contaminated soap

113 Once-weekly epoetin alfa was well tolerated, with most adverse event

114 Epoetin alfa was well tolerated.

115 Epoetin alfa was well tolerated.

116 Epoetin alfa was well tolerated; the most common adverse

117 that preservative-free, single-use vials of epoetin alfa were punctured multiple times, and residual

118 Patients receiving epoetin alfa who had the greatest Hb increases from rand

119 or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarc

120 sized that treating anemia with subcutaneous epoetin alfa would be associated with reverse ventricula